Platelet Enzymatically Oxidized Phospholipids (eoxPL) Characterisation in a Healthy Cohort on and Off Aspirin

NCT05604118 | Completed

• 1 other identifier: SMREC16/02
• Study Type: interventional
• Target: 28
• Locations: 1 country
• Sites: 1

Brief Summary

Healthy volunteers (n = 28) were recruited from the workplace (14 male, 14 female; age range 20-50 years). Ethical approval, which included informed consent, was from Cardiff University, Schools of Medicine and Dentistry Research Ethics Committee (SMREC16/02). Following a 2-week period free from non-steroidal anti-inflammatory drugs (NSAIDs), peripheral blood was obtained and platelets isolated. Participants were commenced on aspirin 75 mg once daily for seven days and then provided a repeat blood sample. Following a 2-month period, participants were invited to repeat samples pre- and post-aspirin, and again a third time 2 months later.

Conditions

Platelet Dysfunction Due to Aspirin

Keywords

platelets; phospholipids; aspirin

Outcome Measures

Primary Outcomes (1)

• Platelet EoxPL differences in amounts (ng) as measured by liquid chromatography with tandem mass spectrometry

  Samples on and off aspirin will be quantified for the 47 most common eoxPL species (as described by Slatter et al, Cell Metabolism 23, 930-944, May 10, 2016) using established liquid chromatography with tandem mass spectrometry (LC-MS/MS). Differences in amounts on and off aspirin will be quantified and tested for statistical significance.

  4 months

Study Arms (2)

Aspirin supplemented

EXPERIMENTAL

Drug: Aspirin

Off aspirin

NO INTERVENTION

Interventions

Aspirin DRUG

1 week of aspirin supplementation prior to sampling

Aspirin supplemented

Eligibility Criteria

• Age: 20 Years - 50 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• two-week washout period from any non-steroidal anti-inflammatory drugs (NSAIDs) use.
• Ability to take aspirin 75 mg once daily for seven days and sampled thereafter, before stopping the aspirin.
• Willingness to repeat this process after two months and four months of the initial sampling date.

You may not qualify if:

• \* Recent NSAID use

Sponsors & Collaborators

• Cardiff University: lead

Study Sites (1)

Sir Geraint Evans Cardiovascular Research Building

Cardiff, CF144XN, United Kingdom

Location

MeSH Terms

Interventions

Aspirin

Intervention Hierarchy (Ancestors)

Salicylates; Hydroxybenzoates; Phenols; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: CROSSOVER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 20, 2022
• First Posted: November 3, 2022
• Study Start: August 1, 2016
• Primary Completion: August 1, 2018
• Study Completion: June 1, 2022
• Last Updated: November 3, 2022

Record last verified: 2022-10

Data Sharing

• IPD Sharing: Will not share

Locations

GB (1)